MedTrace Logo

Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)

NCT04184063 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-09-23

No results posted yet for this study

Summary

In total 20 subjects will be enrolled at one participating site -UMC Ljubljana. The 20 subjects will be treated with placebo and NBMI 300 mg in a cross-over design. In case of subject drop-outs, additional subjects may be enrolled as decided by the Sponsor, to allow for expected number of evaluable subjects in each group.

Conditions

Interventions

DRUG

NBMI

NBMI active treatment

OTHER

Placebo

Placebo for comparison

Sponsors & Collaborators

  • EmeraMed

    lead INDUSTRY

Principal Investigators

  • Tanja Turk, M. Pharm · CRS d.o.o.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-16
Primary Completion
2020-07-30
Completion
2021-06-30

Countries

  • Slovenia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04184063 on ClinicalTrials.gov